XOMA Royalty Corporation has completed its acquisition of Lava Therapeutics N.V., purchasing all outstanding shares for $1.04 in cash per share plus a non-transferable contingent value right. The CVR entitles former Lava holders to 75% of any net proceeds from Lava’s two partnered oncology assets and 75% of any net proceeds from out-licensing or sale of its unpartnered programs, with potential additional payments of up to approximately $0.23 per CVR depending on post-closing liability determinations. Following a tender that captured roughly 91.1% of shares, XOMA executed a corporate reorganization to reach 100% ownership. Lava’s stock was suspended prior to the November 21, 2025 market open and is being delisted from Nasdaq.
The move marks a notable evolution in the royalty-aggregation model. Instead of buying individual royalty streams, XOMA has acquired the corporate shell to control a portfolio of milestone- and royalty-bearing oncology assets, including two early-stage bispecific antibodies partnered with Johnson & Johnson and Pfizer. The structure allows XOMA to manage monetization while handing residual upside to former shareholders through the CVR. The strategic question now is whether this approach signals a broader shift from passive collection to active portfolio stewardship, and whether financial owners can reliably capture value without owning development operations.
For patients and HCPs, near-term continuity likely centers on the partnered programs, which remain anchored within large pharma development engines. That should mitigate operational risk and preserve trial progress, an important consideration in immuno-oncology where study execution, safety management, and combination strategies are complex. The uncertainty lies with unpartnered programs: timelines and indications could be reshaped by XOMA’s out-licensing priorities and buyers’ appetite. Payers are unlikely to see immediate impact, but the downstream competitive mix in hematologic malignancies and solid tumors could shift if these assets find new homes and progress to registrational stages. Competitors in the bispecific and T-cell engager space should take note: financially driven consolidation is reordering who holds the economics of early IO assets, which can influence partnering leverage and milestone pacing.
The transaction underscores several 2025-era trends. First, CVRs are becoming the currency of last-mile biotech exits, reconciling valuation gaps while preserving optionality for public shareholders. Second, royalty aggregators and specialty finance players are stepping into roles once occupied by crossover funds, providing structured liquidity to companies that cannot raise on acceptable terms. Third, big pharma’s reliance on external innovation benefits when distressed partners are replaced by stable counterparties, reducing program discontinuity risk and potential renegotiation friction. For business development teams, this creates a viable exit template for micro-cap companies with valuable partnerships but insufficient runway, and for Medical Affairs leaders at pharma partners, it may streamline governance and data-sharing as asset economics consolidate with a single financial owner.
The next signal to watch is execution speed: how rapidly XOMA translates partnered milestones into cash flows and places unpartnered programs with development owners who can generate the evidence payers will demand. If this model consistently unlocks value, expect more aggregators to buy entire companies rather than single royalty lines, shifting early-stage risk from public equity holders to specialized capital pools. The open question is whether financial ownership will accelerate or slow the clinical and real-world evidence needed to differentiate next-generation bispecifics in crowded oncology pathways.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
